Wall Street Journal - August 27, 1997
Anita Womack

That was in 1960. Now the FDA is considering a new proposal to sell the drug in the U.S.

An FDA panel has scheduled an unusual meeting next week to discuss an application by Celgene Corp. seeking approval of thalidomide for treating leprosy. Celgene is also conducting studies of thalidomide for treating AIDS wasting, a loss of weight and muscle that is a common cause of death in AIDS patients.

Another company, Andrulis Corp., is planning to seek approval to use thalidomide in treating canker sores in AIDS patients.

The question is whether the companies and the FDA can prevent the deformities seen decades ago. The consensus seems to be no, that some accidents will happen.

Still, says Dr. Debra Birnkrant of the FDA, "Clearly if a woman has AIDS and aphthous ulceration [canker sores] then ethically we cannot deny her this product."

"The question is how do you distribute a drug that is a known teratogen -- meaning it causes birth defects -- while assuring access to people who need it," says Sol Barer, president and chief operating officer at Celgene. "I don't think the answer is to prohibit the use of the drug to women of childbearing years."

The issue is causing some distress, however, among victims of thalidomide.

"The last thing we wanted was to deal with a drug like thalidomide," says Randolph Warren, chief executive and co-founder of the Thalidomide Victims Association of Canada. Along with other victims, the 36-year-old Mr. Warren, whose mother was given the drug while in Germany, has fought hard to keep the public informed about the drug's dangers. The association is concerned that as thalidomide is approved for more purposes, the chances grow that it will be taken for uses for which it is not approved.

"We are forced to see regulated thalidomide as opposed to unlicensed availability," he says. "We are not advocating its use [but] we can't deny this to people who can have their lives extended."

In Europe, 125 cases of birth deformity were reported in connection with the drug. Some infants had no legs at all, just toes sprouting from their hips, along with foreshortened, flipper-like arms. And, although it was never approved in the U.S., 17 cases of birth defects were reported in this country, where some people received it as a sample.

The victims group wants the FDA to ensure that patients will not have automatic refills of the drug. And Mr. Warren says the group has Celgene's word that anytime the drug is sold under a brand name, the word thalidomide will also appear.

Dr. Birnkrant, who heads the FDA's Thalidomide Working Group, says, "We do know a lot about thalidomide and know when children are exposed to structural damage." One reason for the large number of birth-defect cases is that thalidomide was prescribed to pregnant women specifically to combat the nausea of morning sickness in the first trimester.

"We have a better understanding about how and when to avoid use," says Dr. Birnkrant, "but that is not to say we won't see other side effects if pregnancies are exposed later in gestation. We don't know."

Dr. Barer believes the answer is to make sure women know the risks and use birth control, and that doctors don't issue automatic refills. The FDA panel next week will attempt to answer the question of how to help women taking the drug prevent pregnancies.

Meanwhile, the National Institutes of Health has scheduled a meeting for Sept. 9 and 10 to publicly address the potential benefits and risks of thalidomide.

The goal of the thalidomide working group is to develop and implement uniform safety-monitoring procedures for all patients, Dr. Birnkrant says. Officials will also set up an accounting system of all patients receiving the drug so they can be followed in the future.

Thalidomide is currently available to a variety of patients on an investigational basis. The patients in those studies, male and female, must use at least two forms of birth control, FDA officials say, and routine pregnancy tests are given to women.

Celgene wants to market thalidomide to treat erythema nodosum leprosum, or ENL, in leprosy patients. Though rare in the U.S., leprosy afflicts 2.4 million people world-wide. About 30% of them suffer from ENL, which is characterized by acute inflammation, fever and loss of appetite. The AIDS wasting population is estimated at 80,000, and Celgene is hoping to capture 20,000 of that population, analysts say. Some analysts say Celgene will sell the drug at $3,000 per person per year at the lowest dosage rate of 100 milligrams per day, but other analysts are unsure of the pricing.

970827
WJ970804

Copyright © 1997 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .